A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382
Authors
Keywords
-
Journal
Oncogenesis
Volume 7, Issue 7, Pages -
Publisher
Springer Nature
Online
2018-07-19
DOI
10.1038/s41389-018-0063-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MTA1-activated Epi-microRNA-22 regulates E-cadherin and prostate cancer invasiveness
- (2017) Swati Dhar et al. FEBS LETTERS
- Targeting NF-κB RelA/p65 phosphorylation overcomes RITA resistance
- (2016) Yiwen Bu et al. CANCER LETTERS
- FOXP1 enhances tumor cell migration by repression of NFAT1 transcriptional activity in MDA-MB-231 cells
- (2016) Sevil Oskay Halacli CELL BIOLOGY INTERNATIONAL
- Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia
- (2016) L M Saleh et al. LEUKEMIA
- miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer
- (2015) Lorenza Pasqualini et al. MOLECULAR ENDOCRINOLOGY
- The microRNA miR-22 inhibits the histone deacetylase HDAC4 to promote TH17 cell–dependent emphysema
- (2015) Wen Lu et al. NATURE IMMUNOLOGY
- Altered radiation responses of breast cancer cells resistant to hormonal therapy
- (2015) Lidiya Luzhna et al. Oncotarget
- A Regulatory Loop Involving miR-22, Sp1, and c-Myc Modulates CD147 Expression in Breast Cancer Invasion and Metastasis
- (2014) L.-M. Kong et al. CANCER RESEARCH
- miR-22 regulates expression of oncogenic neuro-epithelial transforming gene 1, NET1
- (2014) Hafiz M. Ahmad et al. FEBS Journal
- MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling
- (2013) Su Jung Song et al. CELL
- The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and Transformation
- (2013) Su Jung Song et al. Cell Stem Cell
- NFκB signaling is important for growth of antiestrogen resistant breast cancer cells
- (2012) Christina W. Yde et al. BREAST CANCER RESEARCH AND TREATMENT
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the ‘gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)’ 01-Trial in early breast cancer
- (2011) Francesco Boccardo et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2
- (2011) James W. Antoon et al. CANCER BIOLOGY & THERAPY
- Tumor Suppressor miR-22 Determines p53-Dependent Cellular Fate through Post-transcriptional Regulation of p21
- (2011) N. Tsuchiya et al. CANCER RESEARCH
- Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells
- (2011) Jian Li et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- FOXP1, an Estrogen-Inducible Transcription Factor, Modulates Cell Proliferation in Breast Cancer Cells and 5-Year Recurrence-Free Survival of Patients with Tamoxifen-Treated Breast Cancer
- (2011) Takashi Shigekawa et al. Hormones & Cancer
- Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients
- (2010) Mathias Warm et al. BREAST CANCER RESEARCH AND TREATMENT
- microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity
- (2010) J Zhang et al. BRITISH JOURNAL OF CANCER
- An estrogen receptor α suppressor, microRNA-22, is downregulated in estrogen receptor α-positive human breast cancer cell lines and clinical samples
- (2010) Jianhua Xiong et al. FEBS Journal
- MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways
- (2010) X Rao et al. ONCOGENE
- MicroRNAs: Target Recognition and Regulatory Functions
- (2009) David P. Bartel CELL
- Her2 activates NF-κB and induces invasion through the canonical pathway involving IKKα
- (2009) E C Merkhofer et al. ONCOGENE
- CDK Inhibitors: Cell Cycle Regulators and Beyond
- (2008) Arnaud Besson et al. DEVELOPMENTAL CELL
- Cooperative regulation in development by SMRT and FOXP1
- (2008) K. Jepsen et al. GENES & DEVELOPMENT
- Most mammalian mRNAs are conserved targets of microRNAs
- (2008) R. C. Friedman et al. GENOME RESEARCH
- MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1
- (2008) Tyler E. Miller et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Advances in microRNAs: implications for immunity and inflammatory diseases
- (2008) E. Sonkoly et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21
- (2008) Andrew J. Wilson et al. MOLECULAR BIOLOGY OF THE CELL
- Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells
- (2008) V. Duong et al. MOLECULAR CANCER RESEARCH
- Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?
- (2008) Witold Filipowicz et al. NATURE REVIEWS GENETICS
- HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism
- (2008) D Mottet et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started